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Emmeke J Eijkelkamp1, Thomas R Yapp MD2, Lawrie W Powell MD PhD2
Iron overload can result from several different etiologicaldisorders, some inherited and some acquired. The term
‘hemochromatosis’ was first used by von Recklinghausen (1)
and has been widely used to describe the clinicopathological
consequences of iron overload, of whatever etiology, ever
since. Sheldon (2) was the first to suggest that hemochroma-
tosis was an inborn error of iron metabolism with a familial
association. For this reason, we believe that the term ‘hemo-
chromatosis’ should be reserved for primary inherited forms
of iron overload (synonymous with hereditary hemochroma-
tosis [HHC]).
HHC, the inherited form of iron overload, is the most
common autosomal recessive disorder in white populations.
The deposition of iron in the parenchymal cells of the liver,
joints, pancreas, heart, skin and pituitary gland can eventu-
ally lead to fibrosis and organ failure, such as hepatic cirrho-
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MINI-REVIEW
EJ Eijkelkamp, TR Yapp, LW Powell. HFE-associated heredi-
tary hemochromatosis. Can J Gastroenterol 2000;14(2):
121-125. Hereditary hemochromatosis is a common inherited
disorder of the iron metabolism. Screening studies indicate that it
has a prevalence of one in 200 to 400, depending on the popula-
tion studied, and a carrier rate of about one in seven to one in 10.
Feder et al identified the hereditary hemochromatosis gene (HFE)
in 1996 and two candidate mutations; the C282Y mutation has
been shown to be responsible for the majority of the hereditary he-
mochromatosis cases worldwide. The gene discovery has led to
rapid advances in the field of iron metabolism. Although the basic
defect is still not fully understood, much is known about the se-
quence of events leading to iron overload.
Hereditary hemochromatosis is a major candidate for population
screening and meets the screening criteria of the World Health
Organization, and Wilson and Jungner. It is one of the most preva-
lent genetic diseases in white populations, and, importantly, early
diagnosis and simple effective treatment allow normal life expec-
tancy.
The discovery of the HFE gene and the frequency of the single
C282Y mutation as a cause of most cases of hereditary hemochro-
matosis allow the possibility of widespread genetic testing. How-
ever, the logistics, and the psychological and social consequence
of this, coupled with incomplete expression of the genotype, neces-
sitate further studies before population screening can be justified.
Key Words: Hereditary hemochromatosis; HFE; Iron metabolism
Hémochromatose héréditaire associée à l’HFE
RÉSUMÉ : L’hémochromatose héréditaire est une maladie héréditaire
courante du métabolisme du fer. Les études épidémiologiques révèlent que
sa prévalence est de 1 pour 200 ou 400 selon la population étudiée, et le
taux de porteurs serait d’environ 1 pour sept ou dix.
Feder et coll. ont identifié le gène de l’hémochromatose (HFE) en 1996 et
deux mutations candidates; la mutation C282Y s’est révélée responsable de
la majorité des cas d’hémochromatose héréditaire à l’échelle mondiale. La
découverte de ce gène a pavé la voie à de rapides progrès dans le domaine
du métabolisme du fer. Bien que l’anomalie de base ne soit pas encore en-
tièrement élucidée, on comprend bien maintenant la séquence de phé-
nomènes qui conduit à la surcharge ferrique.
L’hémochromatose héréditaire est une importante maladie à dépister
auprès des populations et elle répond aux critères établis à cet égard par
l’Organisation mondiale de la santé et par Wilson et Jungner. Il s’agit de
l’une des maladies génétiques les plus prévalentes au sein de la population
de race blanche et, fait à noter, le diagnostic précoce suivi d’un traitement
simple et efficace donne accès à une espérance de vie normale.
La découverte du gène HFE et la fréquence de la mutation C282Y comme
cause de la plupart des cas d’hémochromatose héréditaire nous permet
d’entrevoir la possibilité de procéder à un dépistage génétique élargi. Par
contre, pour des questions d’ordre logistique, psychologique et social,
alliées à l’expression incomplète du génotype, il faudra poursuivre les
recherches avant de pouvoir justifier le dépistage des populations.
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sis, diabetes mellitus, cardiac dysfunction, arthritis and
hypogonadism (3-8).
Feder et al (9) identified the HHC gene and the two can-
didate mutations in 1996. A single missense mutation, a gua-
nine to adenine transition, leading to a cysteine to tyrosine
substitution at position 282 (C282Y), is responsible for the
majority of the HHC cases worldwide (6,9-11).
PATHOPHYSIOLOGY OF IRON OVERLOAD
Iron balance is regulated by iron absorption (12), which in
turn is reciprocally regulated by the level of body iron stores
(13). In HHC, the enhanced net absorption of 3 to 4 mg/day
results in the accumulation of 500 to 1000 mg of iron/year
during adult life. Increased absorption in HHC occurs in the
context of normal dietary intake and normal levels of
erythropoiesis, and continues parallel with progressively ac-
cumulating iron stores (14). The process of iron absorption
involves uptake from the intestinal lumen into the entero-
cyte, storage of iron in several pools within the enterocyte
and transfer from the enterocyte into the portal circulation
(3). Cellular uptake of iron is both dependent on, and inde-
pendent of, transferrin and the transferrin receptor (TfR),
located on plasma membranes. TfR is a key protein in iron
transport, and modulation of its expression regulates iron up-
take. It has been demonstrated that the normal HFE protein
binds to the TfR, which may attenuate its capacity to trans-
port iron into the cell (15). With the mutated protein, this
binding does not occur, which may lead to increased iron
transport into the cell (3).
Independent of transferrin and TfR, an iron transporter
gene (Nramp2 or DCT-1) has been defined in animal stud-
ies. Expression of Nramp2 or DCT-1 (also called divalent
metal transporter 1) is inversely regulated by cellular iron
concentration; thus, this protein is an ideal candidate for a
regulated brush border iron transporter. The role of this
transporter in human diseases is a subject of major research
interest (3).
The basolateral transport of iron to the circulation is also
an important step in the iron absorption pathway and is
probably the rate-limiting step (16,17). The recent isolation
of a component of this transfer step, a ceruloplasmin homo-
logue known as hephaestin, may hold the key to the under-
standing of this component of the iron absorptive pathway
and to the precise defect in HHC.
How iron leads to tissue damage is still unknown, but pos-
sible mechanisms include iron-induced peroxidative injury
to phospholipids of organelle membranes, in particular, of ly-
sosomes and mitochondria (18,19); activation of iron-
loaded Kupffer cells, which leads to the release of profibro-
genic cytokines (20); and altered matrix degradation (21).
The evidence is overwhelming that it is the tissue iron con-
centration per se that is primarily responsible (22,23).
HFE AND ITS MUTATIONS
Gene discovery: Feder et al (9) identified a candidate HHC
gene in 1996, which has been termed ‘HFE’. The gene lies
4.5 Mb telomeric to human leukocyte antigen and shows
similarity with major histocompatability complex class I
genes. One of the two known mutations is a guanine to ade-
nine transition that results in a substitution of a cysteine
with tyrosine at position 282 (C282Y) (11). Several studies
have confirmed that the C282Y mutation is responsible for
the majority of the phenotypically diagnosed HHC cases
(6,9-11), ie, groups of investigators from several areas of the
world showed that 60% to 100% of white patients with clini-
cally diagnosed HHC were homozygous for the C282Y muta-
tion (9,10,24-27).
Mapping of the whole HFE gene revealed a second muta-
tion – a cysteine to guanine change, causing a histidine to as-
partic acid substitution at position 63 (H63D). However, the
relationship between the H63D mutation and HHC has not
been completely elucidated (11,28), though clearly some
compound heterozygotes (heterozygous for both C282Y and
H63D) show significant iron accumulation but rarely at the
level of C282Y homozygotes (28).
Prevalence and mode of inheritance: HHC has an autoso-
mal recessive mode of inheritance. Screening studies using
serum ferritin (SF) and transferrin saturation (TS) indicate a
prevalence of one in 200 to 400 persons, depending on the
population (4,10,11,29,30), though many patients are
asymptomatic (30). HHC has a carrier rate of about one in
seven (23) to 10 (31,32) individuals. These carriers (hetero-
zygotes) of the C282Y mutation may have an increased iron
absorption, but in isolation, this has no effect, and they are
unlikely to develop any clinical manifestations (29).
As with any autosomal recessive disorder, equal numbers
of men and women are affected, though in all clinical series
men have outnumbered women, often by a substantial mar-
gin. A possible explanation for this sex difference is loss of
iron through menstruation and pregnancy (4).
Role of mutation in the pathophysiology: In the normal hu-
man intestine, HFE binds to beta-2 microglobulin and mi-
grates to the cell surface, where it interacts with the TfR. In
hemochromatosis patients with the characteristic mutation
(C282Y), HFE undergoes a conformational change resulting
in an inability to bind beta-2 microglobulin. As a result, the
HFE protein is trapped within the cell rather than being ex-
pressed on the cell surface. It has been demonstrated (15)
that the normal HFE protein binds to TfR, which may at-
tenuate its capacity to transport iron into the cell. With the
mutated protein, this binding does not occur, which may
lead to increased iron transport into the cell (3).
CLINICAL ASPECTS
The symptoms of HHC are often nonspecific and can be at-
tributed to other causes, so a high index of clinical suspicion
is required in making the diagnosis. The most frequent early
symptoms are lethargy and arthralgia, though patients also
present with abdominal pain, loss of libido or potency, and
secondary amenorrhea. Frequent signs and complications
are hepatomegaly, pigmentation of the skin, arthritis, hypo-
gonadism, diabetes mellitus and changes in cardiac function
(7,8), though their presence usually reflects advanced dis-
ease.
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Particular attention when taking a history should focus
on previous oral and parenteral iron administration, and
causes of blood loss (blood donations, excessive menstrual
blood loss and/or multiple pregnancies). A hematological
examination should be performed for evidence of anemia
and abnormal erythropoiesis to exclude iron loading secon-
dary to a hematological disorder such as thalassemia major or
sideroblastic anemia.
With the widespread use of biochemical and genetic
screening tests, HHC is being recognized earlier in the natu-
ral history of the disease and before symptoms and/or physi-
cal signs develop. Of interest is the large population
screening study performed in Australia (33), which showed
that the prevalence of homozygotes for the C282Y mutation
was 0.05%, but of these, 30% were asymptomatic and with-
out biochemical abnormalities, 20% had hepatic iron over-
load without symptoms and only 25% were cirrhotic.
The relevant biochemical abnormalities of iron metabo-
lism suggesting iron overload due to HHC are as follows.
 TS reflects the basic iron abnormality and is, therefore,
the most sensitive single test for phenotypic
identification of HHC. The normal TS is 30% to 40%
(34,35).
 SF can reflect the amount of tissue iron excess, though,
as an acute phase reactant, it can be elevated by
infection, inflammation and malignancy. The normal
SF range is 10 to 300 µg/L (34,35).
 The measurement of the serum iron level is of limited
value because of numerous variables. The normal serum
iron level is 20 µmol/L (34,36,37).
Liver biopsy is the only practical means of assessing organ
damage (6-8,38). Its role in the diagnosis of HHC was re-
cently redefined by Guyader et al (39). The liver biopsy pro-
vides a semiquantitative evaluation of iron excess using the
hepatic iron index as described by Bassett et al (40) (hepatic
iron concentration/age), which indicates iron overload of
the degree seen in homozygous HHC when greater than 1.9
or 2.0 (35,40,41). Liver biopsy also allows the assessment of
the degree of fibrosis and/or cirrhosis. However, Guyader et
al (39) showed that, though the diagnosis of severe fibrosis
relies on liver biopsy, the absence of severe fibrosis can be ac-
curately predicted in most patients by using simple clinical
and biochemical variables. There is virtually no risk of severe
fibrosis in a C282Y homozygous patient with the following:
SF level less than 1000 µg/L, normal aspartate transaminase
values and no hepatomegaly (39). New techniques of com-
puted tomography and magnetic resonance imaging scan-
ning show potential but are too insensitive for the detection
of fibrosis, especially early in the disease process.
Body iron stores may be assessed accurately by careful
quantitative phlebotomy, though this is retrospective.
HHC can be confidently diagnosed based on genetic test-
ing for the C282Y mutation, particularly if there are in-
creases in TS and/or SF levels or a family history of HHC (6).
However, especially in Southern Italy, non-HFE-associated
familial hemochromatosis has been described (25,34,42).
Family screening: Following the diagnosis of HHC in a
C282Y homozygous proband, it is possible to evaluate the
hemochromatosis risk among family members by assessing
their C282Y status. Two points, however, need to be consid-
ered. The first concerns the chance of lack of clinical expres-
sion in cases of C282Y homozygosity, ie, the degree of
penetrance of this genotypic profile. It is increasingly ac-
knowledged that some homozygous individuals will not de-
velop significant iron overload during their life (3,34,43).
The second point concerns children. In so far as there is no
expected therapeutic decision to be taken during childhood,
screening for HHC, particularly at birth, is not justified. This
is reinforced by the fact that penetrance of the homozygous
status is incomplete (34).
TREATMENT
Removal of iron by phlebotomy therapy is the mainstay of
treatment of HHC (3,44). Once or twice weekly, if toler-
ated, 500 mL of blood (equivalent to 250 mg of iron) should
be removed until the storage iron pool is depleted. In prac-
tice, this may take two to three years for individuals with a
very heavy body iron burden. The SF can be expected to de-
cline progressively during therapy with the greatest fall/mg
of iron removed (1 ng/mL of ferritin per 2 mg of iron) occur-
ring in the early phlebotomies. Serum iron and TS levels
usually remain elevated until iron depletion has occurred.
Usually, they do not fall until the SF level falls below 30 to
50 ng/mL. Estimation of hemoglobin concentration is an
adequate guide to the therapeutic ‘endpoint’; phlebotomy
should continue at weekly intervals until the hemoglobin
concentration falls below 11 g/dL and does not immediately
recover, indicating the development of mild iron deficiency.
The frequency of phlebotomy therapy can then be reduced
to three to six/year to maintain TS at under 30% to 50% and
the SF at less than 50 to 100 µg/L. Lifelong phlebotomy ther-
apy is required, preferably on a regular rather than intermit-
tent basis. Measurement of SF and TS periodically (every
three to six months) is useful to predict phlebotomy require-
ments and is helpful to encourage patients to continue with
therapy (44).
There are no dietary restrictions, but patients are advised
to avoid oral iron therapy, alcohol abuse and vitamin C in-
take (which enhances iron uptake) (3). Chelation therapy
with desferroxamine is not routinely recommended (3) and
is usually reserved for patients who cannot tolerate phlebot-
omy because of heart failure, hypoproteinemia or anemia.
For patients with HHC, phlebotomy not only is more effec-
tive but also is less expensive, more convenient and safer.
PROGNOSIS
The prognosis of symptomatic untreated HHC is poor. Sev-
eral studies show that there is a significant difference in sur-
vival time between untreated and treated patients. The
mean survival of untreated patients was 1.5 to 4.9 years,
whereas the mean survival time of treated patients was 5.3 to
8.2 years (2,7,8,45).
In a study by Niederau et al (8) in 1996, the nonspecific
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symptoms of weakness, lethargy and abdominal pain im-
proved after the initial removal of iron in the majority of pa-
tients. More specific signs of liver disease decreased in more
than 70% of patients, whereas endocrine and joint changes
improved in only 19% to 30% of patients after iron removal.
Insulin dependency could not be eliminated by iron re-
moval, although the daily dose of insulin was reduced in 41%
of patients.
Survival in noncirrhotic and nondiabetic patients was
significantly better than that of cirrhotic and diabetic pa-
tients, and was virtually identical to that expected for a sex-
and age-matched normal population (8,46,47).
The major causes of death in HCC patients are hepato-
cellular carcinoma, cirrhosis and cardiomyopathy (7,8). In
HHC, the risk seems to be mainly restricted to cirrhotic pa-
tients (8), but rare cases without cirrhosis but with fibrosis
and architectural distortion have been described (48-50).
The relative risk of hepatocellular carcinoma in patients
with HHC and cirrhosis is 200-fold (7,38). Men are much
more susceptible to hepatocellular carcinoma than woman
(51,52). For all patients with cirrhosis, the risk of hepatocel-
lular carcinoma increases with time (50). Screening of cir-
rhotic patients for hepatocellular carcinoma with interval
(usually six monthly) ultrasound and alfa-foetoprotein is
recommended, although not conclusively shown to be cost
effective.
The presence of cirrhosis is the single most important
prognostic feature. Cirrhosis is irreversible and not affected
by phlebotomy. For patients with end-stage liver disease due
to HHC, liver transplantation is a therapeutic possibility
(44).
GENERAL POPULATION SCREENING
HHC is a major candidate for population screening (53) be-
cause it is an important health problem. With its high fre-
quency, it is one of the most prevalent genetic diseases in
white populations (more frequent than, for example, phen-
ylketonuria, which is routinely screened for at birth) (4).
Most importantly, early diagnosis and treatment can im-
prove the patient’s prognosis to normal life expectancy
(8,47,53). A suitable and accepted test for early diagnosis is
available, and so are the facilities for the safe and effective
treatment of HHC. There is an agreed policy on whom to
treat. The natural history and clinical course of HHC are
well established in a patient with iron overload. Screening
for HHC would be cost effective and could be a continuing
process (32,54-56). These characteristics meet the screening
criteria of the World Health Organization (3), Wilson and
Jungner (57), and others (4,53-55). The optimal timing for
phenotypic screening is when the patient is under 30 years of
age, at a time when HHC is evident from iron studies in most
patients but before serious organ damage has occurred (6)
(Figure 1).
In considering population screening with the DNA test,
one should be aware of the lack of information about the
penetrance of the genotype, because nonexpressing homozy-
gotes are common, even in elderly subjects (3,4,54). There is
also a lack of information on other, undetected genetic mu-
tations (so called ‘non-HFE-associated HHC’), and about
psychological and social consequences (such as the possibil-
ity of medical and genetic discrimination, and stigmatiza-
tion) (4,53).
Current debate centres on the relative roles of screening
tests. More information is required on the natural history of
the disease and the penetrance of the genetic mutation be-
fore widespread genetic tests can be recommended. How-
ever, early diagnosis and removal of excess iron result in
normal life expectancy and prevent the complications of
iron overload. Thus, family screening is important, and iron
measurements should be part of standard health checks.
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